Tositumomab: Difference between revisions
Content deleted Content added
m Identifier not assigned: use =none (CAS RN, ChemSpider, ATC) (via AWB script) |
→top: Combined with radioisotope iodine 131 & swap 2 sent |
||
| Line 36: | Line 36: | ||
| molecular_weight = 143859.7 g/mol |
| molecular_weight = 143859.7 g/mol |
||
}} |
}} |
||
'''Tositumomab''' was a drug that was approved for the treatment of relapsed or [[chemotherapy]]/[[rituxan]]-[[refractory]] [[Non-Hodgkin lymphoma]] in 2003.<ref>New York Times. July 1, 2003 [http://www.nytimes.com/2003/07/01/business/company-news-corixa-and-glaxo-s-cancer-drug-wins-fda-approval.html Company News: Corixa and Glaxo's Cancer Drug Wins FDA Approval]</ref> |
'''Tositumomab''' was a drug that was approved for the treatment of relapsed or [[chemotherapy]]/[[rituxan]]-[[refractory]] [[Non-Hodgkin lymphoma]] in 2003.<ref>New York Times. July 1, 2003 [http://www.nytimes.com/2003/07/01/business/company-news-corixa-and-glaxo-s-cancer-drug-wins-fda-approval.html Company News: Corixa and Glaxo's Cancer Drug Wins FDA Approval]</ref> |
||
Combined with [[radioisotope]] [[iodine 131]]<ref name=Timmerman2013/> it was sold in the U.S. and Canada under the trade name '''Bexxar'''. |
|||
This drug combination was developed by [[Corixa (company)|Corixa]] which was purchased by [[GlaxoSmithKline]]) in 2005.<ref>Carla Mozee for MarketWatch. April 29, 2005 [http://www.marketwatch.com/story/corixa-agrees-to-glaxo-acquisition-for-300-million Glaxo to acquire Corixa for $300 million]</ref> |
This drug combination was developed by [[Corixa (company)|Corixa]] which was purchased by [[GlaxoSmithKline]]) in 2005.<ref>Carla Mozee for MarketWatch. April 29, 2005 [http://www.marketwatch.com/story/corixa-agrees-to-glaxo-acquisition-for-300-million Glaxo to acquire Corixa for $300 million]</ref> |
||
Sale of Bexxar was discontinued and marketing approval was withdrawn in February 2014 due to the decline in usage (fewer than 75 patients in 2012) and the existence of other similar drugs.<ref name=Timmerman2013>{{cite web | url = http://www.xconomy.com/national/2013/08/26/why-good-drugs-sometimes-fail-in-the-market-the-bexxar-story/ | title = Why Good Drugs Sometimes Fail: The Bexxar Story}}</ref><ref>Notice by the Food and Drug Administration on October 23, 2013. [https://www.federalregister.gov/articles/2013/10/23/2013-24840/glaxosmithkline-llc-withdrawal-of-approval-of-the-indication-for-treatment-of-patients-with-relapsed GlaxoSmithKline LLC; Withdrawal of Approval of the Indication for Treatment of Patients With Relapsed or Refractory, Low Grade, Follicular, or Transformed CD20 Positive Non-Hodgkin's Lymphoma Who Have Not Received Prior Rituximab; BEXXAR]</ref> |
|||
==References== |
==References== |
||
Revision as of 19:32, 18 January 2016
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CD20 |
| Clinical data | |
| Trade names | Bexxar |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a609013 |
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C6416H9874N1688O1987S44 |
| Molar mass | 143859.7 g/mol g·mol−1 |
  (what is this?) (verify) | |
Tositumomab was a drug that was approved for the treatment of relapsed or chemotherapy/rituxan-refractory Non-Hodgkin lymphoma in 2003.[1]
Combined with radioisotope iodine 131[2] it was sold in the U.S. and Canada under the trade name Bexxar.
This drug combination was developed by Corixa which was purchased by GlaxoSmithKline) in 2005.[3]
Sale of Bexxar was discontinued and marketing approval was withdrawn in February 2014 due to the decline in usage (fewer than 75 patients in 2012) and the existence of other similar drugs.[2][4]
References
- ^ New York Times. July 1, 2003 Company News: Corixa and Glaxo's Cancer Drug Wins FDA Approval
- ^ a b "Why Good Drugs Sometimes Fail: The Bexxar Story".
- ^ Carla Mozee for MarketWatch. April 29, 2005 Glaxo to acquire Corixa for $300 million
- ^ Notice by the Food and Drug Administration on October 23, 2013. GlaxoSmithKline LLC; Withdrawal of Approval of the Indication for Treatment of Patients With Relapsed or Refractory, Low Grade, Follicular, or Transformed CD20 Positive Non-Hodgkin's Lymphoma Who Have Not Received Prior Rituximab; BEXXAR
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |